Objectives: Several studies on faecal carriage of extended-spectrum b-lactamase (ESBL)/AmpC-producing Escherichia coli have been performed in cattle, but little is known about faecal carriage in veal calves. This study describes the prevalence and molecular characteristics of ESBL/AmpC genes in E. coli isolated from faecal samples of veal calves from 1997 to 2010.
Introduction
Extended-spectrum cephalosporins (ESCs) are used in both human and veterinary medicine. Resistance to ESCs may lead to therapy failure and is therefore of great concern. 1 Resistance to ESCs in Enterobacteriaceae is mainly caused by production of extendedspectrum b-lactamases (ESBLs) or AmpC b-lactamases. 2 Faecal carriage of ESBL/AmpC-producing bacteria in cattle has been reported previously. 3 -6 However, cattle are kept for different purposes in livestock production. Dairy farms are predominantly closed production systems, while at veal calf farms virtually all animals originate from different farms. Also, the housing facilities, farm management and the lifespan of the animals differ greatly. Furthermore, dairy cattle are generally less exposed to antimicrobials. 7 These differences may lead to differences in prevalence and epidemiology of ESBL/AmpCproducing bacteria. In particular, data on faecal carriage of ESBL/AmpC-producing bacteria in veal calves are limited. The aim of this study was to retrospectively determine the emergence, trends and molecular characteristics of cefotaxime-resistant Escherichia coli in faecal samples obtained from veal calves in the Netherlands from 1997 to 2010.
Materials and methods

Sampling design and method
Faecal samples were collected at farms by the Netherlands Food and Consumer Product Safety Authority (NVWA) from 1997 to 2010 to monitor zoonotic foodborne pathogens in food-producing animals. 
ESBL/AmpC gene identification
All isolates were screened by PCR and sequence analysis for the presence of bla CTX-M , bla TEM , bla SHV and bla CMY and mutations in the promoter region of the chromosomally encoded ampC gene using primers and conditions as described previously. 8 The isolates were also screened for bla OXA group 1, 2 and 10. 9 All positive PCR products were sequenced using a Big Dye Terminator v1.1 cycle Sequencing Kit (Applied Biosystems, USA) with additional primers for bla TEM (TEM-Fseq, 5
′ -GCCAACTTACTTCTGA CAACG) and bla CMY (CMY-F-838, 5
′ -TGGCGTATTGGCGATATGTA; CMY-R-857, 5 ′ -TACATATCGCCAATACGCCA). All sequences were analysed using Sequencher v4.9 (Gene Codes Corporation, USA) and BioNumerics v6.6 (Applied Maths, Belgium). All mutations in the promoter region of the chromosomally encoded ampC gene were identified as described by Mulvey et al. 10 All isolates for which no ESBL/AmpC gene could be determined were screened on the Check-MDR CT-101 array platform (CheckPoints, The Netherlands) according to the manufacturer's protocol.
Statistical analysis
Prevalence data were analysed by a linear regression model with intercept and slope using the open source R statistics software.
Results
The prevalence of cefotaxime-resistant E. coli in both datasets (1997 -2005 and 2006 -10) showed a discontinuous increasing trend, ranging from 4% in 1998 and 1999 to 39% in 2010 (Table 1) The diversity of ESBL/AmpC genes isolated from veal calves from 1997 to 2010 gradually increased (Table 1) . Both the number of gene families and the diversity within gene families increased. In all years from 1997 to 2010, promoter mutations of the chromosomal ampC gene were found. The most commonly found ampC promoter mutation was ampC type 3 ( Table 1) .
The vast majority of ESBL genes found in veal calves from 2000 onwards belonged to the bla CTX-M gene family (Table 1) . In 2010, 65% of all isolates with non-wild-type cefotaxime susceptibility carried genes of the bla CTX-M gene family, of which bla CTX-M-1 was most abundant (39% of all non-wild-type isolates). Other resistance genes belonging to the gene families of bla TEM , bla SHV and bla CMY were found with a relatively low prevalence (Table 1) .
In three isolates no ESBL/AmpC resistance gene could be determined. In these isolates, only the narrow-spectrum b-lactamase bla OXA-1 was identified. Additional testing using the Check-MDR CT101 array also gave a negative result. These isolates were therefore designated 'unknown' ( Table 1) .
Discussion
This study showed an increase in the prevalence and molecular diversity of genes encoding cefotaxime resistance in E. coli from veal calves over a 14 year period. Since the two sets of faecal samples were stored under different conditions, we cannot fully exclude a possible bias between the two sets of samples.
To our knowledge, similar studies on faecal carriage covering a large number of years have not been performed in other countries. In contrast to other studies, we used an enrichment supplemented with cefotaxime to increase the sensitivity of the isolation method. Using different sampling methods and different populations (e.g. dairy cows, veal calves or a mixed population) makes comparing prevalence data rather difficult. The best comparable study was performed in Switzerland, where 63 calves (maximum of 2 per farm) were included in the study and sampled at slaughter in 2009, 2010 and 2011. In that study 25% of the faecal samples were positive for bla CTX-Mproducing E. coli, using EE broth enrichment and subsequently Brilliance ESBL agar. 11 This is similar to the prevalence we found in 2009. In contrast, the prevalence in other cattle (young cows, fattening bulls and bullocks) in this Swiss study was 1.6%, confirming the possible differences in prevalence between different kinds of cattle. Furthermore, in the UK in 2007-08, 7% of farms (mixed cattle population) that submitted faecal samples for diagnostic purposes were positive for bla CTX-Mproducing E. coli. 6 These samples were cultured on selective plates that did not include a selective enrichment broth. In Poland no ESBL/AmpC-producing E. coli were found in 2009 (no enrichment; agar supplemented with 2 mg/L cefotaxime; cattle not further specified). 12 In a study performed in France in 2009, a prevalence of 5% was shown in a mixed population of healthy adults and diseased calves (ESBL screening agar supplemented with 4 mg/L cefotaxime or 4 mg/L ceftazidime). 13 Mutations in the promoter region of the chromosomal ampC were found in all examined years (Table 1 ). All ampC variants except that from 2009 harboured mutations at one or more positions that have been previously described to cause a 'strong' promoter (242, 232, 218, 211, 21, +17 to +37 or +58). Mutations at positions 242 and 232 are especially thought to have a large effect on promoter strength. 14 Our data show that, of all mutations in the chromosomal ampC, ampC type 3
Carriage of ESBL/AmpC-producing E. coli in veal calves from 1997 to 2010 Year   1997  1998  1999  2000  2001  2002  2003  2004  2005  2006  2007  2008  2009  2010   Number of faecal samples screened  49  49  49  47  51  50  23  50  50  152  170  160  180  182 Number (%) with non-wild-type cefotaxime susceptibility 3 (6) 2 (4) 2 (4) 6 (13) 7 (14) 13 (26) 2 (9) 14 (28) 18 (36) 16 (11) 33 (19) 16 (10) (33) 1 (50) 1 (17) 1 (8) 1 (6) 1 (2) 1 (1) pAmpC bla CMY-2 1 (6) 2 (6) 1 (2) 2 (3) ESBLs bla CTX-M-1 1 (17) 2 (15) 1 (7) 3 (17) 4 (25) 8 (24) 5 (31) 12 (27) 28 (39) bla CTX-M-2/97 e 1 (8) 1 (7) 2 (11) 1 (6) 4 (12) 1 (6) 3 (7) 3 (4) bla CTX-M- 14 1 (3) 1 (6) 6 (14) 7 (10) bla CTX-M- 15 1 (7) 2 (11) 2 (13) 3 (9) 3 (19) 4 (9) 3 (4) was most abundant. This was similar to a Canadian study in which samples of human clinical origin were analysed. 10 This study also showed an increasing diversity in plasmidmediated ESBL/AmpC gene families, as well as an increasing number of gene variants within a gene family ( Table 1) . The first ESBL genes in this study were found in 2000. These were bla CTX-M-1 , bla TEM-52 and bla TEM-20 . To our knowledge, in other countries bla CTX-M-1 was not found in cattle until 2003. 15, 16 Furthermore, bla TEM-52 was not reported in cattle until 2004, isolated from Danish cattle meat products imported from Germany, and bla TEM-20 was reported in cattle meat from Tunisia in 2007. 17, 18 From 2007 to 2010 the vast majority of ESBLs in our study were bla CTX-M-1 , followed by either bla CTX-M-15 in 2008 or bla CTX-M-14 in 2009 and 2010. The high prevalence of these three bla CTX-M gene variants is in agreement with what is found in cattle in the rest of Europe, as has been summarized by Ewers et al. 19 In contrast to the low prevalence of TEM ESBLs, TEM b-lactamases, especially bla TEM-1 , were highly dispersed (not shown).
In summary, in the years 1997-2010 both the prevalence and the diversity of different ESBL/AmpC-producing E. coli in veal calves increased. Further research is required to assess transmission between animals in relation to the health risks for the animals themselves, and to assess the relative importance of the food transmission route towards humans.
